## **Core Concept**
The question tests knowledge of antitubercular drugs and their safety profiles, particularly in patients with hepatitis. Hepatotoxicity is a significant concern with many antitubercular drugs. The correct answer must be a drug that is known for having a lower risk of hepatotoxicity.

## **Why the Correct Answer is Right**
The correct answer, **Ethambutol**, is considered relatively safe in patients with hepatitis. Ethambutol primarily causes optic neuritis as its major side effect, rather than hepatotoxicity. This makes it a safer option for patients with pre-existing liver conditions, such as hepatitis.

## **Why Each Wrong Option is Incorrect**
- **Option A: Isoniazid** is incorrect because it is known to cause hepatotoxicity, which can be severe. Isoniazid-induced liver injury is a well-documented side effect, making it a less safe choice for patients with hepatitis.
- **Option B: Rifampicin** is incorrect because it also has the potential for hepatotoxicity. Like isoniazid, rifampicin can cause liver damage, which is a concern in patients with hepatitis.
- **Option C: Pyrazinamide** is incorrect as it is another antitubercular drug associated with hepatotoxicity. Pyrazinamide can cause liver damage, similar to isoniazid and rifampicin, making it less suitable for patients with hepatitis.

## **Clinical Pearl / High-Yield Fact**
A key point to remember is that while ethambutol is safer in hepatitis due to its lower risk of hepatotoxicity, monitoring for optic neuritis (a potential side effect of ethambutol) is crucial. This involves regular assessment of visual acuity and color vision.

## **Correct Answer:** . Ethambutol